GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (NAS:PHVS) » Definitions » Equity-to-Asset

PHVS (Pharvaris NV) Equity-to-Asset : 0.95 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pharvaris NV Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Pharvaris NV's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $329.40 Mil. Pharvaris NV's Total Assets for the quarter that ended in Sep. 2024 was $347.59 Mil.

The historical rank and industry rank for Pharvaris NV's Equity-to-Asset or its related term are showing as below:

PHVS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.87   Med: 0.95   Max: 0.97
Current: 0.95

During the past 7 years, the highest Equity to Asset Ratio of Pharvaris NV was 0.97. The lowest was 0.87. And the median was 0.95.

PHVS's Equity-to-Asset is ranked better than
94.78% of 1512 companies
in the Biotechnology industry
Industry Median: 0.67 vs PHVS: 0.95

Pharvaris NV Equity-to-Asset Historical Data

The historical data trend for Pharvaris NV's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharvaris NV Equity-to-Asset Chart

Pharvaris NV Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.91 0.95 0.97 0.89 0.96

Pharvaris NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.90 0.96 0.95 0.95 0.95

Competitive Comparison of Pharvaris NV's Equity-to-Asset

For the Biotechnology subindustry, Pharvaris NV's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharvaris NV's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharvaris NV's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Pharvaris NV's Equity-to-Asset falls into.



Pharvaris NV Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Pharvaris NV's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=418.809/434.781
=

Pharvaris NV's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Equity to Asset (Q: Sep. 2024 )=Total Stockholders Equity/Total Assets
=329.397/347.586
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharvaris NV  (NAS:PHVS) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Pharvaris NV Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Pharvaris NV's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharvaris NV Business Description

Traded in Other Exchanges
Address
Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.